Advertisement

Recent Advances in Skin Cancer Treatment in Older Adults

  • Anne Lynn S. ChangEmail author

Abstract

Skin cancer rates are increasing in the USA, and the risk of skin cancer increases with age. This chapter reviews the evidence behind the growing number of treatment options available to treat basal cell carcinoma, squamous cell carcinoma, and melanoma, and highlights issues of particular concern to older adults. Research gaps are also discussed.

Keywords

Elderly Skin cancer Basal cell carcinoma Squamous cell carcinoma Melanoma Treatment 

References

  1. 1.
    Kricker A, Armstrong B, Hansen V, Watson A, Singh-Khaira G, Lecathelinais C, et al. Basal cell carcinoma and squamous cell carcinoma growth rates and determinants of size in community patients. J Am Acad Dermatol. 2014;70(3):456–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Rashtak S, Dierkhising RA, Kremers WK, Peters SG, Cassivi SD, Otley CC. Incidence and risk factors for skin cancer following lung transplantation. J Am Acad Dermatol. 2015;72(1):92–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal cell carcinoma. N Engl J Med. 2012;366(23):2171–9.PubMedCrossRefGoogle Scholar
  4. 4.
    McArthur GA, Chapman PB, Robert C, Larkin J, Haanen J, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology. 2014;15(3):323–32.PubMedCrossRefGoogle Scholar
  5. 5.
    Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–71.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Petit JY, Avril MF, Margulis A, Chassagne D, Gerbaulet A, Duvillard P, et al. Evaluation of cosmetic results of a randomized trial comparing surgery and radiotherapy in the treatment of basal cell carcinoma of the face. Plast Reconstr Surg. 2000;105(7):2544–51.PubMedCrossRefGoogle Scholar
  7. 7.
    Smeets NW, Krekels GA, Ostertag JU, Essers BA, Dirksen CD, Nieman FH, et al. Surgical excision vs Mohs’ micrographic surgery for basal-cell carcinoma of the face: randomised controlled trial. Lancet. 2004;364(9447):1766–72.PubMedCrossRefGoogle Scholar
  8. 8.
    Rhodes LE, de Rie M, Enström Y, Groves R, Morken T, Goulden V, et al. Photodynamic therapy using topical methyl aminolevulinate vs surgery for nodular basal cell carcinoma: results of a multicenter randomized prospective trial. Arch Dermatol. 2004;140(1):17–23.PubMedCrossRefGoogle Scholar
  9. 9.
    Thissen MR, Nieman FH, Ideler AH, Berretty PJ, Neumann HA. Cosmetic results of cryosurgery versus surgical excision for primary uncomplicated basal cell carcinomas of the head and neck. Dermatol Surg. 2000;26(8):759–64.PubMedCrossRefGoogle Scholar
  10. 10.
    Olsen CM, Williams PF, Whiteman DC. Turning the tide? Changes in treatment rates for keratinocytic cancers in Australia 2000-2011. J Am Acad Dermatol. 2014;7(1):21–6.CrossRefGoogle Scholar
  11. 11.
    Love WE, Bernhard JD, Bordeaux JS. Topical imiquimod or fluorouracil therapy for basal and squamous cell carcinoma. Arch Dermatol. 2009;145(12):1431–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Micali G, Lacarrubba F, Nasca MR, Ferraro S, Schwartz RA. Topical pharmacotherapy for skin cancer. J Am Acad Dermatol. 2014;6(e1):979.e12.Google Scholar
  13. 13.
    Beutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens ML. Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5 % cream. J Am Acad Dermatol. 1999;41(6):1002–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Geisse JK, Rich P, Pandya A, Gross K, Andres K, Ginkel A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol. 2002;47(3):390–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Shumack S, Robinson J, Kossard S, Golitz L, Greenway H, Schroeter A, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol. 2002;138(9):1165–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Marks R1, Gebauer K, Shumack S, Amies M, Bryden J, Fox TL, et al. Australasian Multicentre Trial Group. Imiquimod 5 % cream in the treatment of superficial basal cell carcinoma: results of a multicenter 6-week dose-response trial. J Am Acad Dermatol. 2001;44(5):807–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Schulze HJ, Cribier B, Requena L, Reifenberger J, Ferrándiz C, Garcia Diez A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe. Br J Dermatol. 2005;152(5):939–47.PubMedCrossRefGoogle Scholar
  18. 18.
    Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomized controlled trial. Lancet Oncology. 2013;14(7):647–54.PubMedCrossRefGoogle Scholar
  19. 19.
    Kopf AW, Bart RS, Schrager D. Curettage-electrodessication treatment of basal cell carcinomas. Arch Dermatol. 1977;113:439–43.PubMedCrossRefGoogle Scholar
  20. 20.
    Hansen TJ, Anderson BE. Electrodessication and curettage for low-risk cutaneous malignancies of the head and neck. Oper Tech Otolaryngol-Head Neck Surg. 2013;24(1):55.CrossRefGoogle Scholar
  21. 21.
    Chren M, Sahay AP, Bertenthal DS, Sen S, Landefeld CS. Quality of life outcomes of treatments for cutaneous basal cell carcinoma and squamous cell carcinoma. J Investig Dermatol. 2007;6:1351–7.CrossRefGoogle Scholar
  22. 22.
    Chiriac A, Mihaila D, Foia L, Solovan C. Basal cell carcinomas in elderly patients treated by cryotherapy. Clin Interv Aging. 2013;8:341–4.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Basset-Seguin N, Ibbotson SH, Emtestam L, Tarstedt M, Morton C, Maroti M, et al. Topical methyl aminolevulinate photodynamic therapy versus cryotherapy for superficial basal cell carcinoma: a 5 year randomized trial. Eur J Dermatol. 2008;18(5):547–53.PubMedGoogle Scholar
  24. 24.
    Cognetta AB, Howard BM, Heaton HP, Stoddard ER, Hong HG, Green WH. Superficial x-ray in the treatment of basal and squamous cell carcinomas: a viable option in select patients. J Am Acad Dermatol. 2012;67(6):1235–41.PubMedCrossRefGoogle Scholar
  25. 25.
    Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day B, et al. Expanded access study of advanced basal cell carcinoma patients treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Chang ALS, Lewis K, Arron ST, Migden M, Solomon J, et al. (2015) Safety and efficacy of vismodegib in elderly patients: analysis of the ERIVANCE BCC and expanded access studies. J Am Acad Dermatol. (in press)Google Scholar
  27. 27.
    Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Wenig BL, Kurtzman DM, Grossweiner LI, Mafee MF, Harris DM, Lobraico RV, et al. Photodynamic therapy in the treatment of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg. 1990;116(11):1267–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Barysch MJ, Eggmann N, Beyeler M, Panizzon RG, Seifert B, Dummer R. Long-term recurrence rate of large and difficult to treat cutaneous squamous cell carcinomas after superficial radiotherapy. Dermatology. 2012;224(1):59–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Patel GK, Goodwin R, Chawla M, Laidler P, Price PE, Finlay AY, et al. Imiquimod 5% cream monotherapy for cutaneous squamous cell carcinoma in situ (Bowen’s disease): a randomized, double blind, placebo-controlled trial. J Am Acad Dermatol. 2006;54:1025–32.PubMedCrossRefGoogle Scholar
  31. 31.
    Salim A, Leman JA, McColl JH, Chapman R, Morton CA. Randomized comparison of photodynamic therapy with topical 5-fluorouracil in Bowen’s disease. Br J Dermatol. 2003;148:539–43.PubMedCrossRefGoogle Scholar
  32. 32.
    Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2014 Mar 12. doi: 10.1002/hed.23684. [Epub ahead of print]
  33. 33.
    Ciocan D, Barbe C, Aubin F, Granel-Brocard F, Lipsker D, Velten M, et al. Distinctive features of melanoma and its management in elderly patients. JAMA Dermatol. 2013;149(10):1150–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Richardson BS, Anderson WF, Barnholtz-Sloan JS, Tucker MA, Gerstenblith MR. The age-specific effect modification of male sex for ulcerated cutaneous melanoma. JAMA Dermatol. 2014;150(5):522–5.PubMedCrossRefGoogle Scholar
  35. 35.
    Grotz TE, Puig CA, Perkins S, Ballman K, Hieken TJ. Management of regional lymph nodes in the elderly melanoma patient: patient selection, accuracy and prognostic implications. Eur J Surg Oncol. 2014;0748–83.Google Scholar
  36. 36.
    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemburafenib in melanoma with BRAF V600E mutation. NEJM. 2011;364:2507–16.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Long GV, Stoyakovskiy H, Gogas E, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. NEJM. 2014;37:1877–88.CrossRefGoogle Scholar
  38. 38.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEJM. 2010;363(8):711–23.PubMedCentralPubMedCrossRefGoogle Scholar
  39. 39.
    Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013;369(2):134–44.PubMedCentralPubMedCrossRefGoogle Scholar
  40. 40.
    Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without BRAF mutation. NEJM. 2015;372:320–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of DermatologyStanford University School of MedicineRedwood CityUSA

Personalised recommendations